41 completed. 41 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 41 | Completed 41 |
| Phase 2 | 1 | Completed 1 |
Follow Allergic Conjunctivitis: new trials by email Literature Review of Allergic Conjunctivitis trials Research Report on Allergic Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy REGN5713, REGN5715, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 54 | 2024-11-19 | 2026-04-21 |
| A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy REGN1908, REGN1909, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 64 | 2024-11-06 | 2026-05-08 |
| Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 512 | 2023-04-20 | 2025-07-10 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035% - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 188 | 2022-10-12 | 2025-02-14 |
| The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 131 | 2022-01-21 | 2026-05-14 |
| Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children Bilastine, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Faes Farma, S.A. | 59 | 2021-03-26 | 2023-03-16 |
| The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 95 | 2019-12-05 | 2024-11-20 |
| A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis Dexamethasone, 0.4mg, Placebo plug with no drug - Allergic Conjunctivitis | Phase 3 | Completed | Ocular Therapeutix, Inc. | 96 | 2019-08-05 | 2021-10-07 |
| Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray Rhinocort, Budesolv, Placebo - Allergic Rhinitis, Allergic Conjunctivitis | Phase 3 | Completed | Marinomed Biotech AG | 82 | 2018-11-19 | 2020-10-12 |
| A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Faes Farma, S.A. | 228 | 2018-04-07 | 2023-03-16 |
| A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle EM-100, Zaditor®, Vehicle - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 65 | 2018-04-07 | 2023-06-08 |
| ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 318 | 2018-03-30 | 2025-02-11 |
| Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle - Allergic Conjunctivitis | Phase 3 | Completed | Alcon Research | 383 | 2014-12-01 | 2017-11-17 |
| A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle AC-170 0.24%, AC-170 0% - Allergic Conjunctivitis | Phase 3 | Completed | Aciex Therapeutics, Inc. | 101 | 2013-06-01 | 2017-11-09 |
| Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis AL-4943A ophthalmic solution, Olopatadine hydrochloride ophthalmic solution, 0.2%, Olopatadine hydrochloride ophthalmic solution, 0.1% - Allergic Conjunctivitis | Phase 3 | Completed | Alcon Research | 902 | 2013-01-01 | 2014-08-11 |
| A Six-Week Safety Study of an Investigational Ophthalmic Solution AL-4943A Ophthalmic Solution, AL-4943A Ophthalmic Solution Vehicle - Allergic Conjunctivitis | Phase 3 | Completed | Alcon Research | 518 | 2012-10-01 | 2014-03-27 |
| A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle AC-170 0.24%, AC-170 0% - Allergic Conjunctivitis | Phase 3 | Completed | Aciex Therapeutics, Inc. | 100 | 2012-09-01 | 2017-10-10 |
| A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) AC-170 0.24%, AC-170 0% - Allergic Conjunctivitis | Phase 3 | Completed | Aciex Therapeutics, Inc. | 91 | 2012-03-01 | 2017-11-07 |
| An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis AKF-1 - Allergic Conjunctivitis | Phase 3 | Completed | Akorn, Inc. | 90 | 2012-03-01 | 2013-07-18 |
| Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model AL-4943A ophthalmic solution, AL-4943A vehicle, Olopatadine hydrochloride ophthalmic solution, 0.2% - Allergic Conjunctivitis | Phase 3 | Completed | Alcon Research | 397 | 2012-01-01 | 2013-06-04 |
Showing 20 of 41. Sign in to see all of them.
Conjunctivitis, Allergic (41) · Hypersensitivity (3) · Rhinitis, Allergic (2) · Rhinitis, Allergic, Seasonal (2) · Nasal Obstruction (1)
Conjunctival Diseases (41) · Conjunctivitis (41) · Eye Diseases (41) · Hypersensitivity, Immediate (41) · Immune System Diseases (41) · Hypersensitivity (38) · Nose Diseases (2) · Otorhinolaryngologic Diseases (2) · Respiratory Hypersensitivity (2) · Respiratory Tract Diseases (2) · Rhinitis (2) · Airway Obstruction (1) · Respiration Disorders (1) · Respiratory Insufficiency (1)
Ketotifen (6) · Olopatadine Hydrochloride (6) · Ophthalmic Solutions (3) · Brimonidine Tartrate (2) · Naphazoline (2) · bepotastine besilate (2) · Budesonide (1) · Contact Lenses (1) · Dexamethasone (1) · alcaftadine (1) · bilastine (1) · bromfenac (1) · ketotifen fumarate ophthalmic solution (1)
Bausch & Lomb Incorporated (9) · Vistakon Pharmaceuticals (8) · Alcon Research (7) · Aciex Therapeutics, Inc. (4) · Aldeyra Therapeutics, Inc. (3) · Faes Farma, S.A. (2) · Regeneron Pharmaceuticals (2) · Santen Pharmaceutical Co., Ltd. (2) · Akorn, Inc. (1) · Marinomed Biotech AG (1) · Ocular Therapeutix, Inc. (1) · Stallergenes Greer (1)
United States (25) · Canada (4) · Japan (3) · Austria (1) · Czechia (1) · Denmark (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Latvia (1) · Lithuania (1) · Poland (1) · Slovakia (1) · Spain (1)
Brian Pall, OD, MS, FAAO (4) · Abhijit Narvekar, MS, MBBS (2) · Edward Meier, MD (2) · Ingerman Avner, MD (2) · Stacey Ackerman, MD (2) · Tim McNamara, PharmD (2) · Dawn DeCastro, MD (1) · Eugene McLaurin, MD (1) · Eugene Protzko, MD (1) · Eva E Prieschl-Grassauer, PhD (1) · Gail L Torkildsen, MD (1) · Gail Torkildsen (1) · Jack Greiner, DO (1)
PMID 27466061, PMID 20488431, PMID 21250860, PMID 22991696, PMID 24517417, PMID 25163405, PMID 26266427, PMID 36811846, PMID 38105911, PMID 39328900
2016 (1), 2018 (1)